2.08
-0.02(-0.95%)
Currency In USD
| Previous Close | 2.1 |
| Open | 2.03 |
| Day High | 2.12 |
| Day Low | 2.01 |
| 52-Week High | 5.17 |
| 52-Week Low | 1.05 |
| Volume | 513,000 |
| Average Volume | 1.12M |
| Market Cap | 225.33M |
| PE | -1.32 |
| EPS | -1.57 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 1.98 |
| Change | -0.02 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $189.09 as of September 09, 2025 at a share price of $2.08. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $967.44 as of September 09, 2025 at a share price of $2.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics to Participate in Two September Healthcare Conferences
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
GlobeNewswire Inc.
Jul 29, 2025 8:01 PM GMT
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerabili
Aclaris Therapeutics Announces Leadership Transition
GlobeNewswire Inc.
Jul 28, 2025 12:45 PM GMT
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28